title: Injection of ethanolamine oleate into a segmental portal branch for pharmacologic hepatic segmentectomy in dogs.
abstract: OBJECTIVE
  Currently available treatments for hepatocellular carcinoma are not satisfactory in terms of recurrence rates. In this study, we injected ethanolamine oleate (EO) into a portal branch in an attempt to cause necrosis of a liver segment in which hepatocellular carcinoma might be located.
  
  
  METHODS
  Nine dogs received EO injections via a balloon catheter into a segmental portal branch of the liver.
  
  
  RESULTS
  Immediately after injection, 80-100% of the liver cells in the EO-injected segment underwent coagulative necrosis. After 1 week, the EO-injected segment had become completely necrotic in two dogs. Only a few viable hepatocytes were still observed around the arteries and beneath the liver capsule in another dog. No pathologic changes were observed in the lungs, kidneys, or heart of any dog. There was a correlation between the EO dosages and the volume of the EO-injected liver tissue.
  
  
  CONCLUSIONS
  EO injection into a portal branch results in the pharmacologic destruction of the corresponding liver segment. This procedure may be beneficial in the treatment of hepatic malignancies.
authors.affiliation: Third Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Iwasaki
authors.forename: N
authors.initials: N
authors.lastname: Chida
authors.forename: S
authors.initials: S
authors.lastname: Suzuki
authors.forename: T
authors.initials: T
authors.lastname: Akahane
authors.forename: N
authors.initials: N
authors.lastname: Kobayashi
authors.forename: M
authors.initials: M
authors.lastname: Ishii
authors.forename: T
authors.initials: T
authors.lastname: Toyota
mesh_terms: D000818:Animals; D002404:Catheterization; D003287:Contrast Media / Q000008:administration & dosage; D004195:Disease Models, Animal; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D006498:Hepatectomy / Q000379:methods*; D007275:Injections, Intravenous; D007479:Iopamidol / Q000008:administration & dosage; D008099:Liver / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D008106:Liver Cirrhosis, Experimental / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology; D009829:Oleic Acids / Q000008:administration & dosage*; D011169:Portal Vein; D011172:Portography; D012597:Sclerosing Solutions / Q000008:administration & dosage*; D015911:Sclerotherapy / Q000379:methods*; D000637:Transaminases / Q000097:blood
chemical_list: D003287:Contrast Media; D009829:Oleic Acids; D012597:Sclerosing Solutions; D000637:Transaminases; D007479:Iopamidol; C033343:ethanolamine oleate